Group 1 - Cabot Corporation declared a quarterly dividend of $0.45 per share on all outstanding shares of its common stock, payable on September 11, 2025, to stockholders of record at the close of business on August 29, 2025 [1] - Cabot Corporation is a global specialty chemicals and performance materials company headquartered in Boston, Massachusetts, providing a range of products including reinforcing carbons, specialty carbons, battery materials, and more [2] Group 2 - The company is listed on the New York Stock Exchange under the ticker symbol CBT [2]

VANCOUVER, British Columbia, July 11, 2025 (GLOBE NEWSWIRE) -- Global Uranium Corp. (CSE: GURN | OTC: GURFF | FRA: Q3J) (the “Company”) is pleased to announce that Ungad Chadda has been appointed as director of the Company. Mr. Chadda, who also serves Chief Executive Officer of the Company, is an experienced capital markets regulator and financial services executive having previously worked at TMX Group, the parent company of Toronto Stock Exchange. At TMX Group, Mr. Chadda was responsible for building and ...

Core Viewpoint - The FDA issued a Complete Response Letter (CRL) for Ultragenyx's Biologics License Application (BLA) for UX111, a gene therapy for Sanfilippo syndrome type A, citing specific chemistry, manufacturing, and controls (CMC) observations that are resolvable [1][2] Group 1: Company Overview - Ultragenyx Pharmaceutical Inc. is focused on developing therapies for rare and ultra-rare genetic diseases, with a diverse portfolio aimed at addressing high unmet medical needs [6] - The company is led by a management team experienced in rare disease therapeutics, emphasizing time- and cost-efficient drug development [7] Group 2: Product Information - UX111 is an in vivo gene therapy in Phase 1/2/3 development for Sanfilippo syndrome type A (MPS IIIA), a rare fatal lysosomal storage disease with no approved treatment [4] - The therapy targets the SGSH enzyme deficiency, which leads to the accumulation of heparan sulfate in the brain, causing neurodegeneration [4] - UX111 is administered via a one-time intravenous infusion using a self-complementary AAV9 vector to deliver a functional copy of the SGSH gene [4] Group 3: Regulatory Status - The FDA's CRL did not raise any issues regarding the clinical data package or clinical inspections, acknowledging the robustness of the neurodevelopmental outcome data and supportive biomarker data [3] - The company plans to address the CMC observations and resubmit the BLA, anticipating a review period of up to 6 months post-resubmission [2][3] Group 4: Disease Context - Sanfilippo syndrome type A (MPS IIIA) affects approximately 3,000 to 5,000 patients in commercially accessible areas, characterized by rapid neurodegeneration and a median life expectancy of 15 years [5] - The disease is caused by biallelic pathogenic variants in the SGSH gene, leading to a deficiency in the sulfamidase enzyme [5]

Core Insights - LGI Homes, Inc. has launched its new community, Crystal Creek, in the Nashville market, featuring townhomes with included upgrades and convenient access to local amenities [1][2]. Company Overview - LGI Homes is headquartered in The Woodlands, Texas, and operates in 36 markets across 21 states, having closed over 75,000 homes since its inception in 2003 [6]. - The company is recognized for its quality construction and exceptional customer service, earning accolades such as being named to Newsweek's list of the World's Most Trustworthy Companies [6]. Community Features - Crystal Creek offers two-story townhomes with three bedrooms and two-and-a-half bathrooms, ranging from 1,794 to 1,952 square feet [4][11]. - Homes are equipped with the CompleteHome Plus™ package, featuring upgraded amenities at no additional cost, including chef-ready kitchens with Whirlpool® appliances and smart-home technology [4]. - The community includes various amenities such as parks, multi-purpose fields, and shaded walking trails connecting to the City of Spring Hill Greenway [3]. Pricing and Availability - Move-in ready homes in Crystal Creek start in the mid-$400s, with potential buyers encouraged to schedule appointments or visit the information center [5].

Core Insights - Precipio, Inc. has amended its warrant exercise agreement with its largest warrant holder, changing the structure from cash exercise to a combination of cash and cashless exercise, resulting in a cash inflow of approximately $1.2 million instead of $3.8 million [1][6] Company Overview - Precipio is a healthcare biotechnology company focused on cancer diagnostics, aiming to reduce cancer misdiagnoses through innovative diagnostic products and services that enhance accuracy and improve patient outcomes [3] Financial Impact - The amendment to the warrant exercise will reduce the number of shares added to the company's outstanding shares from approximately 300,000 to between 130,000 and 150,000, depending on the share price at the time of exercise [6]

Core Viewpoint - Wabash (NYSE: WNC) will host a quarterly earnings conference call to discuss its financial results for Q2 2025 on July 25, 2025, at 12:00 p.m. ET [1]. Group 1: Earnings Call Details - The earnings call will be accessible via a conference call number and will also be available for replay shortly after the presentation [2]. - Related materials, including the earnings press release and slides, will be posted on Wabash's website by 7:00 a.m. ET on the day of the call [2]. Group 2: Company Overview - Wabash is a leader in connected solutions for the transportation, logistics, and distribution industries, focusing on innovative products and services [3]. - The company designs and manufactures a variety of products, including trailers and specialty food-grade processing equipment, aimed at enhancing customer operations [3].

Core Viewpoint - MidWestOne Financial Group, Inc. is set to release its second quarter 2025 financial results on July 24, 2025, followed by a conference call on July 25, 2025 to discuss these results [1]. Financial Results Announcement - The financial results for the second quarter of 2025 will be announced after market closes on July 24, 2025 [1]. - A conference call to discuss the financial results will take place at 11:00 a.m. Central Time on July 25, 2025 [1]. Participation Details - Investors and analysts can pre-register for the conference call via a provided link [2]. - On the day of the call, participants can dial in approximately 15 minutes before the start time using specific access codes [2]. Replay Information - A replay of the conference call will be available within four hours after the call concludes and can be accessed online or via a dedicated phone number [3]. - The replay will remain available until October 23, 2025 [3]. Company Overview - MidWestOne Financial Group, Inc. is a financial holding company based in Iowa City, Iowa, and is the parent company of MidWestOne Bank [4]. - The bank operates in Iowa, Minnesota, Wisconsin, and Colorado, providing electronic financial services through its website [4]. - The company is listed on the Nasdaq Global Select Market under the ticker symbol "MOFG" [4].

SOUTHAMPTON, Pa., July 11, 2025 (GLOBE NEWSWIRE) -- Environmental Tectonics Corporation (OTC Pink: ETCC) (“ETC” or the “Company”) today reported its financial results for the thirteen week period ended May 30, 2025 (the “2026 first fiscal quarter”). Robert L. Laurent, Jr., ETC’s Chief Executive Officer and President stated, “We are pleased with the 39% increase in ETC operating income vs. prior year driven by an increase in sales of Aircrew Training Systems (“ATS”) and a decrease in operating expenses as co ...

JENA, Germany, July 11, 2025 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics by targeting the complement system, today announced that it has received a written notice (the “Notice”), dated July 11, 2025, from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”) indicating that, for the last thirty (30) consecutive business days, the bid price for the Company’s common shares had closed below the minimum $1.00 pe ...

Core Insights - Solitron Devices, Inc. reported a decline in revenue for the first quarter of fiscal 2026, consistent with the previous quarter, due to delays in order fulfillment. The company anticipates a sales increase by the end of the second quarter and a more stable revenue level in the third quarter [1][4] Financial Performance - Net sales decreased by 32% to approximately $2.70 million in the first quarter of fiscal 2026 compared to $3.97 million in the same quarter of fiscal 2025 [7] - Net bookings increased by 37% to $2.80 million in the first quarter of fiscal 2026, up from $2.04 million in the prior year [7] - The backlog rose by 94% to $18.26 million at the end of the first quarter of fiscal 2026, compared to $9.41 million at the end of the first quarter of fiscal 2025 [7] - The company reported a net loss of $0.34 million, or $0.16 per share, for the first quarter of fiscal 2026, compared to a net income of $0.59 million, or $0.28 per share, for the same quarter in fiscal 2025 [7][8] Investment Activities - The company invested $1.65 million for a 6.4% stake in CBE LLC, which acquired a 25% interest in CrossingBridge Advisors for $25.9 million. This investment is expected to yield a royalty of approximately 14.9% of CrossingBridge's revenue [3] Market Opportunities - The U.S. Air Force has requested an increase in AMRAAM production from 1,200 to 2,400 units annually by 2028, which is significant as AMRAAM is the largest defense program supplied by Solitron. However, this increase requires Congressional approval [4] - The company is seeing increased interest in new product development, particularly in silicon carbide, and has developed various prototypes for testing [5][4]